Publications and Presentations
Discovery, Expression, and Characterization of Neutralizing Picobodies against SARS-CoV2
At 4-6 KD, “picobodies” represent the smallest known Ig-derived binding moiety capable of high affinity interactions with target proteins.
Antibody Discovery Powered By OmniAb
The OmniAb platform couples cutting edge screening and data mining technologies with highly validated antibody generation systems.
Chicken Heavy Chain only antibodies to SARS-CoV2
Single domain antibodies are found naturally in camelids and sharks, and humanized versions have been engineered.
Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics
Bispecific antibodies are an important and growing segment in antibody therapeutics, particularly in the immuno-oncology space. Manufacturing of a bispecific antibody with…
Comparisons of the antibody repertoires of a humanized rodent and humans by high throughput sequencing
The humanization of animal model immune systems by genetic engineering has shown great promise for antibody discovery, tolerance studies and for the evaluation of vaccines…
Expression of human lambda expands the repertoire of OmniChickens
Most of the approved monoclonal antibodies used in the clinic were initially discovered in mice. However, many targets of therapeutic interest are highly conserved…
OmniTaur™: Ultralong CDR3 cow antibodies for challenging targets
Bovine antibodies are unusual in having exceptionally long heavy chain CDR3 regions, with an average length of 25 amino acids, and an ‘ultralong’ subset that can reach >70 amino acids in length…